Malignant Melanoma | Pharmacor | G7 | 2014

The poor prognosis of advanced malignant melanoma (melanoma) patients means that there is a significant need for effective therapies to treat patients in this indication and a large commercial opportunity for drug developers. Immunotherapy treatments have actively been researched in melanoma and have received approval. Furthermore, the launch of BRAF and MEK inhibitors for BRAF-mutation-positive melanoma has segmented the market according to patients’ BRAF-mutation status, a trend that looks set to continue. With the entry of novel immunotherapies and BRAF and MEK inhibitors, the melanoma market is set to become increasingly competitive as agents vie for patient share.

Login to access report